Navigation Links
AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
Date:12/28/2007

MARKHAM, ON, Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX - News), a leader in the development of Nanotechnology for Drug Delivery Platforms, announce that in order to meet TSX Venture Exchange listing requirements, its CEO, CFO, directors, consultants and employees plan to exercise stock options to purchase 3,300,000 shares of AlphaRx common stock. Michael Lee, President and CEO, will cancel 6,000,000 options granted to him in 2004 which carried a strike price of $0.15 a share and will exercise 1,862,228 warrants with a strike price of $0.10 a shares. Furthermore, certain company employees will voluntarily cancel 1,710,000 of their options at the same time to make the capital structure of the company more attractive for institutional investors. The company expects to complete these transactions on or before Dec 31, 2007.

In conjunction of the above transactions, Michael Lee will purchase 6,000,000 company shares at a price of $0.15 a share under a private placement. The company expects to close this private placement on or before January 31, 2008.

The shares issued from the exercise of options, warrants and the private placement are subject to applicable hold periods and trading restrictions under the US Securities Act of 1933 and may only be offered, sold or otherwise transferred outside the US or inside the US in accordance with applicable exemptions from registration.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx To Present at 47th Annual ICAAC
2. AlphaRx Announces Debt Conversion
3. Ohio Dental Association Installs New President and Officers
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
7. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. William Moore Appointed to IRIDEX Board of Directors
11. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Coalition Duchenne, a Newport Beach, California based charity committed ... in the April 25 U.S. Food and Drug Administration advisory committee hearing on ... the Marriott Conference Center in Hyattsville, Maryland was attended by over than a ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted Reproductive ... are required to report in vitro fertilization (IVF) delivery rates to ... practice of assisted reproductive technologies in the United States. , This year, ...
(Date:4/29/2016)... ... 2016 , ... The number of chronically and seriously ill individuals is growing. ... an urgent need for highly skilled care managers and care coordinators. Care ... train and retain care managers, and enhance their skills. , Care Excellence ...
(Date:4/28/2016)... ... April 29, 2016 , ... Monthly subscription boxes are all the ... They recently reviewed the ZEN BOX , the aromatherapy subscription box. , ZEN ... oils (like lavender or frankincense) and one Zen Blend (like immune boost, sublime sleep ...
(Date:4/28/2016)... ... 2016 , ... Sanford Health’s work in cellular therapy and ... and leaders from Sanford Health were selected to participate in the “ Third ... and receive the 2016 Pontifical Key Innovation Award at the Vatican. , The ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
Breaking Medicine Technology: